Sansum Diabetes Research Institute | Santa Barbara, CA

Research site

Location

2219 Bath Street, Santa Barbara, California, United States of America

Website

https://sansum.org/

Site insights

Top conditions

Top treatments

hydrocortisone

Acetaminophen

PRM-151

Zinpentraxin Alfa

Tirzepatide

Glucose

medroxyprogesterone

Estradiol

Empagliflozin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

5 of 88 total trials

Acceptability & Impact of a Diabetes Management Smartphone App (mySugr) for Spanish-literate Adults With Type 2 Diabetes

The goal of this clinical trial is to compare those using a diabetes management smartphone application (mySugr) to those not using the application. T...

Enrolling

Diabetes Mellitus, Type 2

Behavioral: Smartphone diabetes management application

In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

The objective of the study is to assess the safety and effectiveness of MiniMed™ 780G system in adult subjects with insulin-requiring type 2 diabetes...

Enrolling

Type 2 Diabetes Treated With Insulin

Device: MiniMed™ 780G Insulin Pump system

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes (INHALE-GDM)

Pregnant women aged 18-49 with gestational diabetes (GDM) will take part in this study. We want to see how two different insulin treatments affect th...

Not yet enrolling

Pregnancy Complications

Diabetes, Gestational

Drug: Inhaled Technosphere Insulin

Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with typ...

Enrolling

Type 1 Diabetes

Device: Subject's Current Diabetes Therapy

Device: 670G and 770G Insulin Pump

Omnipod 5 System Compared to Pump Therapy

Subject will undergo a 14-day outpatient, standard therapy phase during which sensor and insulin data will be collected. This will be followed by a 9...

Active, not recruiting

Type 1 Diabetes

Device: Omnipod 5 System